<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6498">
  <stage>Registered</stage>
  <submitdate>15/05/2017</submitdate>
  <approvaldate>15/05/2017</approvaldate>
  <nctid>NCT03163550</nctid>
  <trial_identification>
    <studytitle>A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789</studytitle>
    <scientifictitle>A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and the Drug-Drug Interaction Potential of Oral ACHN-383 and ACHN-789 in Healthy Subjects and to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ACHN-383 and ACHN-789 in Otherwise Healthy Subjects With Renal Impairment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACHN-172-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
    <healthcondition>Otherwise Healthy Volunteers With Renal Impairment</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ACHN-383
Treatment: drugs - ACHN-789
Treatment: drugs - Placebo

Experimental: Cohort 1 - Healthy volunteers

Experimental: Cohort 2 - Healthy volunteers

Experimental: Cohort 3 - Healthy volunteers

Experimental: Cohort 4 - Healthy volunteers

Experimental: Cohort 5 - Otherwise healthy volunteers with moderate renal impairment and (optional) healthy volunteer matched controls

Experimental: Cohort 6 - Otherwise healthy volunteers with moderate renal impairment and (optional) healthy volunteer matched controls


Treatment: drugs: ACHN-383
Oral dose

Treatment: drugs: ACHN-789
Oral dose

Treatment: drugs: Placebo
Oral dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes from baseline in clinical laboratory values (CBC, serum chemistry, urine analysis, AST, ALT, ALP, serum bilirubin)</outcome>
      <timepoint>26 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes from baseline in vital signs (temperature, pulse, respiration, blood pressure)</outcome>
      <timepoint>26 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence and severity of adverse events</outcome>
      <timepoint>26 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes from baseline in the QTcF interval</outcome>
      <timepoint>19 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Maximum peak observed concentration (Cmax) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Maximum peak observed concentration (Cmax) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Time to maximum concentration (Tmax) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Time to maximum concentration (Tmax) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Area under the concentration-time curve (AUC) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Area under the concentration-time curve (AUC) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Half-life (t1/2) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Half-life (t1/2) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Apparent systemic clearance (CL/F) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Apparent systemic clearance (CL/F) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Apparent volume of distribution (Vz/F) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Apparent volume of distribution (Vz/F) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Amount excreted in urine (Ae) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Amount excreted in urine (Ae) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Renal clearance (CLr) after single-dose administration of ACHN-789</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Renal clearance (CLr) after single-dose administration of ACHN-383</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Cmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Tmax after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: AUC after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: t1/2 after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CL/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Vz/F after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Ae after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CLr after single-dose administration of ACHN-383 and ACHN-789 given concurrently 30 minutes after a high-fat, high-calorie meal</outcome>
      <timepoint>6 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Cmax after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Cmin after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Tmax after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: AUC after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: t1/2 after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CL/F after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Vz/F after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: Ae after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter: CLr after multiple-dose administration of ACHN-383 and ACHN-789 given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine concentrations of ACHN-789 after single dose administration</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine concentrations of ACHN-383 after single-dose administration</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine concentrations of ACHN-383 and ACHN-789 after single-dose administration given concurrently</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine concentrations of ACHN-383 and ACHN-789 after single-dose administration given concurrently</outcome>
      <timepoint>5 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urine concentrations of ACHN-383 and ACHN-789 after multiple-dose administration given concurrently</outcome>
      <timepoint>19 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Females of child-bearing potential must not be breast feeding, must have a negative
             serum pregnancy test, and must use a highly effective method of contraception or be
             abstinent from sexual activity prior to the first dose of study, during the study and
             for a specified period following the last dose of study drug

          -  Males must be willing to use a condom for the duration of the study and for a
             specified period following the study, unless surgically sterile. In addition, their
             female partner must use a highly effective method of contraception, for the same
             period of time, unless surgically sterile

          -  Body mass index (BMI) of =19 kg/m^2 to =32 kg/m^2 and weight =50 kg to =125 kg

          -  For subjects with no renal impairment, normal renal function as determined by
             creatinine clearance (CLcr) rate

          -  For subjects with moderate renal impairment, severity of impairment as determined by
             CLcr rate

          -  For subjects with severe renal impairment, severity of impairment as determined by
             CLcr rate

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant women

          -  History of any hepatic or biliary disorder or disease

          -  Any condition that could possibly affect oral drug absorption

          -  Unstable cardiovascular disease

          -  Uncontrolled hypertension, asthma, diabetes, thyroid disease, or seizure disorder

          -  HIV positive

          -  Active malignancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>17/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>10/09/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Clinical Site - Perth</hospital>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Achaogen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase 1 clinical study is a double-blind, randomized, placebo-controlled, parallel group
      study to assess the safety, tolerability, pharmacokinetics (PK), food effect, and drug
      interaction potential of ACHN-383 and ACHN-789 co-administered orally as separate capsules in
      healthy subjects and otherwise healthy subjects with moderate or severe renal impairment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03163550</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel J Cloutier, PharmD</name>
      <address>Achaogen, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Trials Support</name>
      <address />
      <phone>650-800-3636</phone>
      <fax />
      <email>clinical-trials@achaogen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>